GEN Exclusives

More »

GEN News Highlights

More »
May 22, 2007

Javelin Pharmaceuticals Signs Supply Pact with Baxter Healthcare

  • Baxter Healthcare inked a commercial supply agreement with Javelin Pharmaceuticals to provide additional manufacturing capacity for Javelin's injectable diclofenac, Dyloject™.

    Dylojectinjectable diclofenac sodium is under review for marketing approval in the U.K. for the treatment of acute moderate-to-severe pain. In the U.S., Dyloject is in Phase III trials for the same indication.

    Baxter will serve as a secondary manufacturer of Dyloject pending regulatory approval. The deal, which supplements an existing collaboration, has a three-year, renewable term and sets forth minimum purchase and production requirements.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »